You are here: Industry Insights > Market News > Vivimed Labs receives $ 7.5 million fund from OrbiMed Asia

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!

Note: You can unsubscribe from the alerts at any time.

Advertising

New Products

Halal Aloe Vera Extract Powder 10:1

Halal Aloe Ferrox Extract powder10:1

BioCana™ Sealer 呼吸袋封口机

BioCana™ SUT 一次性使用生物工艺耗材系统

BioCana™ 超净湿热灭菌防护罩(Tyvek® 1421B)

BioCana™ APS 无菌药用低密度聚乙烯膜/袋

Vivimed Labs receives $ 7.5 million fund from OrbiMed Asia

expressbpdJanuary 02, 2018

Tag: Vivimed Labs , Healthcare

Favorites

The additional funds will be utilised to fuel growth opportunities

Vivimed Labs has received additional investment of $ 7.5 million (over Rs 47 crore) from healthcare investment firm OrbiMed Asia in its subsidiary Vivimed Labs (Mascarene).

The company had earlier received $ 42.5 million from OrbiMed Asia in September 2017, Vivimed Labs said in a BSE filing.

The overseas subsidiary is the holding entity of the company’s active pharmaceutical ingredient (API) business, it added.

This additional follow on investment by OrbiMed Asia reiterates the confidence of the investor in the Vivimed business model in the health care industry, Vivimed Labs MD Santosh Varalwar said.

"The additional funds will fuel its growth opportunities overall," he added.

Previous:Mylan-Biocon’s breast cancer biosimilar gets ANVISA nod

Next:Some of FDA’s Major Policy Goals For 2018

Thrombolytic Science Announces FDA’s IND Clearance of Mutant Prourokinase for the Treatment of Thrombotic Diseases

PharmaSourcesOctober 15, 2024

Thrombolytic Science, LLC (TSI), announced today that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for mutant prourokinase, a recombinant fibrinolytic pro-enzyme.

Eleva Appoints Dr. Elisabeth Lackner to its Supervisory Board Adding Broad Biopharmaceutical Industry Expertise to the Organization

PharmaSourcesOctober 15, 2024

BrainDos™ Formulated Dual GIP/GLP-1 Receptor Agonist Tirzepatide Outperforms Tirzepatide Solution (Mounjaro®) in Preclinical Study

PharmaSourcesOctober 15, 2024

Vivimed Labs receives $ 7.5 million fund from OrbiMed Asia | Pharmasources.com

BD and ten23 health® Partner to Advance Efficiency and Quality in Aseptic Manufacturing with RFID-Enabled Prefillable Syringes

PharmaSourcesOctober 15, 2024

BD and ten23 health today announced a collaboration to develop a new way to track prefillable syringes (PFS) using RFID technology.

You may like
More>>

White PE HDPE PP Pet Plastic Amber Solid Pill Bottle Healthcare Supplement 200ml

Pet Plastic Amber Solid Pill Bottle Healthcare Supplement Container Withscrew Cap 150ml

Wholesale Healthcare Supplement Food Cosmetic Grade Alpha-lipoic Acid Powder,

Pet Plastic Amber Solid Pill Bottle Healthcare Supplement Container Withscrew Cap 180ml

Pet Plastic Amber Solid Pill Bottle Healthcare Supplement Container Withscrew Cap 70ml

Pet Plastic Amber Solid Pill Bottle Healthcare Supplement Container Withscrew Cap 40ml

Hot Selling Healthcare Supplement L-Proline

Healthcare Products Chaga Mushroom Extract /Chaga polysaccharide

Wellgreen Plant Factory Healthcare Supplement CAS 5985-28-4 Citrus Aurantium Synephrine Extract

Pet Plastic Amber Solid Pill Bottle Healthcare Supplement Container Withscrew Cap 300ml

Vivimed Labs receives $ 7.5 million fund from OrbiMed Asia

Related News

Thrombolytic Science Announces FDA’s IND Clearance of Mutant Prourokinase for the Treatment of Thrombotic Diseases

Eleva Appoints Dr. Elisabeth Lackner to its Supervisory Board Adding Broad Biopharmaceutical Industry Expertise to the Organization

BrainDos™ Formulated Dual GIP/GLP-1 Receptor Agonist Tirzepatide Outperforms Tirzepatide Solution (Mounjaro®) in Preclinical Study

BD and ten23 health® Partner to Advance Efficiency and Quality in Aseptic Manufacturing with RFID-Enabled Prefillable Syringes

You may likeMore>>

You may like
More>>